Trial Summary

Title
Chemotherapy with or without bevacizumab for ovarian cancer, primary peritoneal cancer or fallopian tube cancer (ICON7)

Summary paragraph
This trial is looking at chemotherapy combined with monoclonal antibody therapy as first line treatment for ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

Doctors usually treat ovarian cancer with surgery and chemotherapy. They commonly use the chemotherapy drugs carboplatin and paclitaxel (Taxol).

Bevacizumab (Avastin) is a type of immunotherapy called a monoclonal antibody. Researchers think that giving bevacizumab as well as chemotherapy may be better than chemotherapy alone. But they are not sure yet. All treatments have side effects, and it important that people don’t have treatment they don’t need.

The aim of this trial is to find out if adding bevacizumab to chemotherapy helps stop ovarian cancer coming back after surgery.

Start/End dates
Start: October 2006
End: February 2009

Phase - 3
[Type of trial - treatment]
[Type of treatment – chemotherapy and immunotherapy]

Chief Investigator: Dr T Perren

Supported by: Cancer Research UK Medical Research Council (MRC)

[Keywords] [Dr T Perren, Cancer Research UK, Medical Research Council, MRC, trial, clinical trial, research, cancer research, study, research study, ovarian cancer trial, primary peritoneal cancer trial, fallopian tube cancer trial, ovarian cancer research, primary peritoneal cancer research, fallopian tube cancer research, ovarian cancer clinical trial, primary peritoneal cancer clinical trial, fallopian tube cancer clinical trial, immunotherapy trial, immunotherapy research, biological therapy trial, biological research, bevacizumab, Avastin, bevacizumab trial, Avastin trial]

 The above trial summary was provided by Cancerhelp UK.